Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O14931

UPID:
NCTR3_HUMAN

ALTERNATIVE NAMES:
Activating natural killer receptor p30; Natural killer cell p30-related protein

ALTERNATIVE UPACC:
O14931; B0S8F2; B0S8F4; B0S8F5; O14930; O14932; O95667; O95668; O95669; Q5ST89; Q5ST90; Q5ST91; Q5ST92; Q5STA3

BACKGROUND:
The protein Natural cytotoxicity triggering receptor 3, with alternative names activating natural killer receptor p30 and natural killer cell p30-related protein, is integral to immune surveillance. By binding to ligands like BAG6 and NCR3LG1, it activates NK cells, facilitating their cytotoxic action against cells presenting these ligands, including tumor cells. This receptor also plays a role in the maturation of dendritic cells, a process vital for effective immune response.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Natural cytotoxicity triggering receptor 3 offers promising avenues for developing novel immunotherapies. Its critical role in NK cell activation and dendritic cell maturation presents opportunities for targeted cancer therapies and enhancing immune system responses.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.